<DOC>
	<DOCNO>NCT02767752</DOCNO>
	<brief_summary>This single center , randomize , double-blind , placebo-controlled phase II trial compare efficacy T-ChOS combination gemcitabine gemcitabine alone adjuvant treatment 6 month patient surgically resect pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Gemcitabine Capecitabine With Without T-ChOS Adjuvant Therapy Patients With Resected Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Signed informed consent 2 . Histologically confirm resected ductal pancreatic adenocarcinoma macroscopic complete resection ( R0 R1 ) . Subjects neuroendocrine ( mixed type ) tumor exclude 3 . Subject able start treatment later 12 week postsurgery 4 . Male nonpregnant , nonlactating female ≥18 year age time sign informed consent form ( ICF ) 5 . ECOG/WHO Performance Status ( PS ) 01 6 . Females childbearing potential ( define sexually mature woman ( 1 ) undergone hysterectomy [ surgical removal uterus ] bilateral oophorectomy [ surgical removal ovary ] ( 2 ) naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) must : Agree use two physicianapproved contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study IP ; 3months follow last dose IP Has negative serum pregnancy test ( βhCG ) result screen 7 . Male subject : • Must practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 6 month follow IP discontinuation , even undergone successful vasectomy 8 . Understand voluntarily sign ICF prior study related assessment procedure conduct 9 . Be able adhere study visit schedule protocol requirement 10 . Acceptable hematology parameter define : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10⁹/L Platelet count ≥ 100 x 10⁹/L Haemoglobin ≥ 5.6 mmol/L 11 . Acceptable liver function define : Serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) ASAT/ALAT &lt; 2.5 x ULN 12 . Acceptable renal function creatinine clearance ≥ 50 mL/min/ ( e.g. , use CockroftGault formula ) 1 . Prior neoadjuvant treatment , radiation therapy , systemic therapy pancreatic adenocarcinoma 2 . Presence history metastatic locally recurrent pancreatic adenocarcinoma 3 . Other malignancy , except adequately treat basal carcinoma squamous cell carcinoma skin situ cervix carcinoma incidental prostate cancer ( T1a , Gleason score ≤ 6 , PSA &lt; 0.5 ng/ml ) , tumor DSF survival ≥ 5 year 4 . History serious concurrent illness uncontrolled medical disorder ; medical condition might aggravate chemotherapy treatment could control ; include , restrict : Active infection require antibiotic within 2 week study inclusion Concurrent congestive heart failure NYHA class III IV Unstable angina pectoris , myocardial infarction within 6 month and/or prior poorly control hypertension History interstitial lung disease , slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy Concomitant use immunosuppressive myelosuppressive medication would opinion investigator , increase risk serious neutropenic complication 5 . Known suspected allergy investigational agent agent give association trial 6 . Any psychological , familial , sociological , geographical condition permit protocol compliance medical followup 7 . Enrollment clinical protocol investigational study interventional agent assessment may interfere study procedure 8 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 9 . Any condition confound ability interpret data study 10 . Unwillingness inability comply study procedures 11 . Current use anticoagulation therapy heparin unfractionated low molecular weight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Resectable pancreatic cancer</keyword>
	<keyword>Adjuvant</keyword>
</DOC>